RDNT
RadNet, Inc.
RDNT offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has a slight edge over RDNT overall, supported by stronger modeled upside and lower modeled downside.
RDNT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
RDNT's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
RDNT PE Valuation
RDNT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
RDNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for RDNT, with profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
RDNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | — |
| Q3 2026 | -$0.28 | -$0.11 |
| Q2 2026 | -$0.26 | -$0.06 |
| Q1 2026 | -$0.17 | +$0.26 |
| Q4 2025 | -$0.25 | -725% |
| Q3 2025 | -$0.17 | -$0.17 |
| Q2 2025 | -$0.20 | -195% |
| Q1 2025 | -$0.43 | -216% |
| Q4 2024 | $0.04 | -20% |
RDNT is still losing money, but less than at its worst: $0.28 per share over the past year, against $0.43 at its worst in early 2025.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over RDNT on earnings quality, reporting a profit while its opponent remains loss making.
RDNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $638.3M | +22% |
| Q2 2026 | $622.7M | +25% |
| Q1 2026 | $575.6M | +22% |
| Q4 2025 | $547.7M | +15% |
| Q3 2025 | $522.9M | +13% |
| Q2 2025 | $498.2M | +8.4% |
| Q1 2025 | $471.4M | +9.2% |
| Q4 2024 | $477.1M | +13% |
RDNT has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.7% | -0.5 points |
| Q2 2026 | 6.3% | +0.1 points |
| Q1 2026 | -4.2% | +1 points |
| Q4 2025 | 5.1% | -0.1 points |
| Q3 2025 | 5.2% | -2.1 points |
| Q2 2025 | 6.2% | -1.4 points |
| Q1 2025 | -5.1% | -7.7 points |
| Q4 2024 | 5.1% | -0.7 points |
RDNT's operating margin was 4.7% last quarter, down 0.5 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over RDNT on profitability, with a higher operating margin.
RDNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +$42.7M |
| Q2 2026 | $37.8M | -44% |
| Q1 2026 | $9M | +$16.4M |
| Q4 2025 | $33.1M | +$33.5M |
| Q3 2025 | -$7.6M | -147% |
| Q2 2025 | $67.4M | -2.8% |
| Q1 2025 | -$7.4M | +$33M |
| Q4 2024 | -$377K | -101% |
RDNT generated $115M in free cash flow over the past year, up 121% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over RDNT on cash flow, with more consistent year-over-year improvement.
RDNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +443K shares |
| 1 year | +2.3% | +1.8M shares |
| 3 years | +15% | +10.4M shares |
| 5 years | +47% | +25.4M shares |
| Available history | +57% | +28.9M shares |
RDNT has 79M diluted shares, up 2.3% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over RDNT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
RDNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.1x | Healthy |
RDNT's net debt is about 2.3 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over RDNT on leverage, with a lower net debt burden relative to earnings.
RDNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.3 | Neutral |
| Stochastic | 65.1 | Neutral |
RDNT's weekly RSI is 60 (neutral) and its Stochastic is 65 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
RDNT PE vs Healthcare Sector
| Metric | RDNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RDNT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
RDNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.0 | 5.6% above |
| 20 week MA | $71.2 | 6.8% above |
| 50 week MA | $66.8 | 14% above |
| 100 week MA | $65.1 | 17% above |
| 200 week MA | $54.2 | 40% above |
RDNT has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
RDNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.9 | $18.7 | -5.8% |
| 2021 | $18.7 | $30.4 | +62% |
| 2022 | $30.4 | $18.9 | -38% |
| 2023 | $18.9 | $34.8 | +84% |
| 2024 | $34.8 | $71.3 | +105% |
| 2025 | $71.3 | $73.2 | +2.6% |
| 2026 YTD | $73.2 | $76.0 | +4% |
RDNT has finished higher in four of the last six years, three of them by more than 50%. It's up 4% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over RDNT on returns for 2026, with the stronger performance.